( oducts:Cumulase(R) and Hylenex for us...)Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society,Health

Safe Harbor Statement

In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the applicability of rHuPH20 to large protein molecule therapeutics) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.

    Halozyme Contact                  Investor Relations Contact

    David A. Ramsay                   Don Markley

    Chief Financial Officer           Lippert/Heilshorn & Associates

    (858) 794-8881                    (310) 691-7100

                  


                                      Media Contacts

                                      Karen Sparks / Joleen Schultz

                                      Mentus

                                      (858) 455-5500, x275/x215